OR WAIT null SECS
© 2023 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Thomson Reuters released a report that provides a view of the challenges facing companies entering the United States biosimilar drug market.
The IP & Science business of Thomson Reuters released a life sciences report, “An Outlook on U.S. Biosimilar Competition,” which provides a view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.
While the US continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space, the report says. The report compares US and EU regulations to underscore the significant differences between these regions and explore ways the US can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the US market, including Amgen, Hospira, and Sandoz, among the top pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the US.